Arrowhead Research | ARWR - Ebit


Arrowhead Research reported $-141.26M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Incyte USD 700.4M 356.23M Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Ligand Pharmaceuticals USD 60.33M 1.76M Mar/2026
Merck USD 840M 2.72B Jun/2026
Moderna USD -815M 573M Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Novartis USD 4.73B 549M Jun/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026
Xencor USD -77.86M 24.23M Mar/2026